An Evolution in the Treatment of HIV
With treatment, people living with HIV are now expected to have a near normal life expectancy.
- Based on results from the Antiretroviral Therapy Cohort Collaboration, a 20-year-old starting HIV therapy during 2008 to 2010 can expect to see their 78th birthday.2
- The majority of time on therapy is spent maintaining virological suppression.2
Streamlining therapy to 2 drugs following suppression can reduce ARV exposure and potential associated toxicities3
- JULUCA▼ preparatomtale
- The Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017;1-9 (published online May 10). http://dx.doi.org/10.1016/S2352-3018(17)30066-8. Accessed July 18, 2017.
- Llibre JM, Hung CC, Brinson C, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet 2018;391(10123):839–849.